Preferential Display (PD) based PROTECT system

Period of Performance: 06/02/2004 - 06/02/2006

$750K

Phase 2 SBIR

Recipient Firm

Genexpress Informatics, Inc.
13091 Ponds Springs Road, Suite 150
Austin, TX 78729
Principal Investigator

Research Topics

Abstract

During the Phase I, GeneXpress Informatics (GXI) provided proof-of-concept for the Preferential Display (PD) technology. GXI's Preferential Display (PD) technology is a paradigm shift in high throughput gene expression and analysis. The PD technology eliminates redundant sequences found between tissue types or conditions by using a novel combination of biomolecular chemistry methods and fluorescence dye assay techniques. In this Phase II, GXI proposes to optimize the PD technology by expanding the usage to other cell lines which are of interest to the Air Force. GXI intends to perform the optimization of the PD protocols for these cell lines and will also investigate alternative methodologies and transition the technology into a viable commercial enterprise. GXI also intends to pursue the assembly of a high throughput PD gene expression laboratory to provide gene based drug target databases and contract services for pharmaceutial and Air Force needs for target validation and metabonomics gene expression. As a final deliverable, GXI will provide the Air Force with PD assay kits which will include reagents, assay protocols and a internal standard.